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Objective Enteric glial cells (EGC) have been
suggested to participate in host–bacteria cross-talk,
playing a protective role within the gut. The way EGC
interact with microorganisms is still poorly understood.
We aimed to evaluate whether: EGC participate in host–
bacteria interaction; S100B and Toll-like receptor (TLR)
signalling converge in a common pathway leading to
nitric oxide (NO) production.
Design Primary cultures of human EGC were exposed
to pathogenic (enteroinvasive Escherichia coli; EIEC) and
probiotic (Lactobacillus paracasei F19) bacteria. Cell
activation was assessed by evaluating the expression of
cFos and major histocompatibility complex (MHC) class II
molecules. TLR expression in EGC was evaluated at both
baseline and after exposure to bacteria by real-time PCR,
fluorescence microscopy and western blot analysis.
S100B expression and NO release from EGC,
following exposure to bacteria, were measured in the
presence or absence of specific TLR and S100B
pathway inhibitors.
Results EIEC activated EGC by inducing the expression
of cFos and MHC II. EGC expressed TLR at baseline.
Pathogens and probiotics differentially modulated TLR
expression in EGC. Pathogens, but not probiotics,
significantly induced S100B protein overexpression and
NO release from EGC. Pretreatment with specific
inhibitors of TLR and S100B pathways abolished
bacterial-induced NO release from EGC.
Conclusions Human EGC interact with bacteria and
discriminate between pathogens and probiotics via a
different TLR expression and NO production. In EGC, NO
release is impaired in the presence of specific inhibitors
of the TLR and S100B pathways, suggesting the
presence of a novel common pathway involving both TLR
stimulation and S100B protein upregulation.
INTRODUCTION
The gastrointestinal tract is the main gateway
between the outside environment and the inner
body. It acts as the first defence barrier against
microorganisms and its ability to discriminate
between harmful or healthy bacteria is pivotal to
preserve the intestinal homeostasis. The preserva-
tion of the intestinal environment is ensured by the
efficient host–bacteria interaction and depends on a
complex interplay between the microbiota, the
innate immune system and several cell types resident
in the lamina propria.1 Based on recent evidences,
enteric glial cells (EGC) seem to cooperate with
other cells (ie, immune and epithelial cells) to main-
tain homeostasis in the intestinal milieu.2 3 In par-
ticular, EGC control epithelial barrier functions by
inhibiting intestinal epithelial cell proliferation and
by reducing epithelial permeability via the release of
glial-derived factors, such as transforming growth
factor β and S-nitrosoglutathione,4 5 as demon-
strated in in-vitro and ex-vivo models of Shigella
flexneri invasion.6 7 An emerging concept from
these preliminary reports is that EGC may protect
the host against invading pathogens, probably con-
tributing to the regulation of the host–bacteria inter-
action. However, whether human EGC are activated
Significance of this study
What is already known on this subject?
▸ EGC regulate intestinal homeostasis and are
involved in intestinal inflammation.
▸ Glial cells in the central nervous system express
TLR.
▸ Human-derived EGC produce NO in response to
exogenous proinflammatory stimuli.
What are the new findings?
▸ Human-derived EGC express TLR.
▸ TLR expression in human-derived EGC is
differently modulated by pathogenic and
probiotic bacteria.
▸ Pathogenic, but not probiotic bacteria,
stimulate the release of NO in human-derived
EGC via the involvement of both TLR and
S100B\RAGE.
How might it impact on clinical practice in
the foreseeable future?
▸ This study, highlighting the role of
human-derived EGC in the host–bacteria
interaction, adds further data in the field of
bacteriotherapy. In addition, as these cells can
respond adequately to bacterial insults (ie,
releasing NO), they might be regarded as a
novel and potentially pharmacological target to
modulate nitrosative stress within the gut.
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by bacteria and which pathways are involved in the EGC–bacteria
interaction have not yet been investigated.
Data from the central nervous system indicate that astrocytes,
the EGC equivalent in the brain, are directly involved in the regu-
lation of host–bacteria interaction by acting as resident antigen-
presenting cells and via the expression of Toll-like receptors
(TLR).8 9 Barajon et al10 also reported that TLR3, TLR4 and
TLR7 are expressed by enteric neurons and glial cells in mouse
intestine. It is also conceivable that human EGC express TLR.
Although these observations indicate that enteric glia might be
activated by bacteria, they do not provide any explicit evidence
of their involvement in the crosstalk with intestinal microbiota.
Whether bacteria are able to modulate TLR expression on EGC
and what their putative involvement may be in this interaction
remain to be elucidated.
TLR stimulation leads to the expression of a broad number of
genes involved in the innate and adaptive immunity against
pathogens, including inducible nitric oxide synthase (iNOS).11 12
Nitric oxide (NO) is a pro-inflammatory molecule that enhances
antibacterial response.13 We have previously reported that, in
humans, EGC-derived S100B protein regulates NO production
in intestinal mucosa and that this mechanism is mediated by
interaction with the receptor for advanced glycation endproducts
(RAGE),14 15 which is also involved in the TLR signalling
pathway.16 S100B-mediated NO production has been observed
in intestinal biopsies of patients with coeliac disease and ulcera-
tive colitis. Whether similar mechanisms also play a role in
bacteria-induced EGC activation is unknown.
In this study, we aimed first to investigate the ability of
human EGC to interact directly with bacteria and, second, to
evaluate whether pathogenic or probiotic bacteria are able to
modulate TLR expression on EGC differentially. We also tested
whether EGC respond to bacteria by releasing NO and what the
pathways involved in this response may be.
MATERIALS AND METHODS
EGC isolation, culture, purification and characterisation
Primary cultures of EGC were obtained according to the
method previously described by our group.17 Briefly, specimens
of human small bowel were taken from patients undergoing
surgery for colorectal cancer (four men, mean age 57±4 years;
four women, mean age 59±6 years). All procedures were
approved by the ethics committee of the ‘Federico II’ University
of Naples (protocol no 106/2010). After removal, the tissue was
dissected to expose the myenteric plexus. After digestion
(30 min at 37°C in an enzymatic solution containing protease
and collagenase)18 ganglia were cultured with 1 ml of
DMEM-F12 supplemented with 10% heat-inactivated fetal calf
serum, 1% antibiotic-antimycotic solution and 1% sodium pyru-
vate (all reagents from Sigma) and kept in an incubator at 37°C,
continuously gassed with 95% oxygen–5% carbon dioxide.
After 3–4 weeks, EGC were purified using Dynal-Magnet
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), accord-
ing to the manufacturer’s instructions and to the method we
have previously described.17 19 The separation step with dyna-
beads was performed twice in order to eliminate residual fibro-
blasts/smooth muscle cells within the culture. The resulting
EGC enriched cultures (∼500×103 cells/ml) were characterised
by immunofluorescence and, as previously reported, contamin-
ating cells were virtually absent.17 After an average of five pas-
sages, EGC were exposed to different experimental conditions,
as listed below. EGC isolated from each tissue served for a single
set of experiments.
Bacterial strains
To evaluate the interaction of EGC with different strains of
bacteria, enteroinvasive Escherichia coli (EIEC), a
Gram-negative bacteria, was chosen for its deleterious effects on
the gastrointestinal tract,20 while Lactobacillus paracasei ssp
paracasei F19 (LP F19), a Gram-positive bacteria, was chosen
for its beneficial effect.21 EIEC (ATCC, Rockville, Maryland,
USA) was cultured at 37°C under anaerobic conditions in TSB
(Oxoid, Cambridge, UK). LP F19 (kindly provided by Arla
Foods, Stockholm, Sweden, international publication no WO
99/29833) was grown in the same conditions in MRS broth
(Oxoid). Bacterial stocks were prepared from high cell density
fermentation and cultures were counted and diluted in MRS
agar (2%) or TSB agar (2%) to correlate optical density (OD; at
A600 nm) to cell concentrations. An OD of 1 was adjusted to
1.9×109 colony-forming units/ml for EIEC and to 3.4×108 -
colony-forming units/ml for LP F19. The EGC/bacteria ratio, at
the time of infection, was determined by measuring the OD of
bacterial culture and then calculating the appropriate volume to
add to EGC.
Cell stimulation
To investigate TLR expression in EGC, pathogen EIEC and pro-
biotic strain LP F19 were added to the culture medium of
7 days EGC enriched cultures. Based on our preliminary experi-
ments, we chose to expose EGC to a low bacterial charge (bac-
teria/EGC ratio was 1/10), for 6 and 24 h, to minimise cell
mortality (data on cell mortality are reported as supplementary
data, available online only). Control experiments (basal) were
performed using the medium alone, and pH values of the
medium were measured before and after bacterial infection (see
supplementary data, available online only). Experiments were
realised using both the viable and the heat-inactivated bacteria,
or with the bacterial-derived soluble factors. Heat inactivation
was effected by heating the bacterial suspension at 100°C for
1 h. Soluble factor-containing media were generated by incubat-
ing bacteria in DMEM-F12 at 37°C for 2 h; media were then
centrifuged twice and supernatants were filtered (0.2 mm).
To prove the effective functionality of TLR on EGC, we
exposed EGC for 24 h to both the TRL2 agonist zymosan
(100 μg/ml; Sigma, Milan, Italy), TLR3 agonist poly (I:C)
(50 μg/mll; Imgenex Corp., San Diego, California, USA), TLR4
agonist lipopolysaccharide (10 μg/ml; Sigma), in the presence or
absence of MyD88 homodimerisation-blocking peptide (20 μg/ml;
Imgenex), added 24 h before exposure to agonists; then we
analysed the protein expression of nuclear factor κB (NF-κB)
(p50 subunit).
In a second set of experiments, S100B expression and NO pro-
duction were evaluated after 24 h in the presence or absence of
either S100B-blocking antibody (AbCam, Cambridge,
Massachusetts, USA),22 RAGE-blocking antibody (R&D Systems,
Minneapolis, Minnesota, USA),23 or MyD88 homodimerisation-
blocking peptide (Imgenex),24 each added 24 h before EGC
infection with bacteria.
RNA isolation, reverse transcription and quantitative
real-time PCR
RNA was extracted from EGC using trizol reagent (Invitrogen
SRL, San Giuliano Milanese, Italy) according to the manufac-
turer’s instructions. The RNA quality and concentration was
determined using a nanodrop spectrophotometer (Celbio, Milan,
Italy). Extracted RNAwas treated with a DNA-free kit (Ambion,
Austin, Texas, USA), according to the manufacturer’s
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instructions. Complementary DNA synthesis from Dnase-
digested RNA was performed using the iScript cDNA synthesis
kit (Bio-Rad Laboratories, Hercules, California, USA).
Quantitative real-time PCR for TLR messenger RNA was per-
formed on an iCycler instrument (Bio-Rad), using iQ Syber
Green mastermix (Bio-Rad).25 Primers were taken either from
sequences published elsewhere,26 27 or from Beacon Designer
software (Premier Biosoft, Palo Alto, California, USA) and
selected to anneal to adjacent exons. See supplementary table S1
(available online only) for primer sequences. After each reaction,
a melting curve was used to confirm the specificity of the PCR
products. The ΔΔCT method was used for quantisation of TLR
mRNA expression in stimulated cells compared to unstimulated
cells,28 where the cycle threshold (CT) is the cycle at which the
signal detected is significantly above the background signal, ΔCT
is the difference between the CT of the TLR gene of interest
and the CT of the endogenous control gene β-actin and
ΔΔCT=ΔCT TREATMENT−ΔCT BASAL. Because of differing primer
efficiencies, the CT was calculated normalising efficiency values
to that of β-actin. Data are expressed as fold of increase in TLR
mRNA expression in EGC stimulated with bacteria, compared to
EGC cultured in medium alone (basal), after normalisation to
β-actin mRNA. Each experiment was performed in triplicate. For
comparative purposes, as previously reported in the literature,29
estimation of the absolute mRNA levels for TLR under basal
conditions was made categorising ΔCT values for each TLR into
different ranges of expression: high expression correlating with
small ΔCT (≤5), intermediate expression with 5<ΔCT>15, low
or very low expression with ΔCT ≥ 15 and ΔCT ≥ 40 cycles
equivalent to undetected.
Protein extraction and western immunoblot analysis
We analysed protein expression of three specific TLR, namely
TLR2, TLR3 and TLR4, after a 24 h-challenge with bacteria. We
chose to characterise these TLR better because TLR2 and TLR4
recognise mainly Gram-positive and Gram-negative bacteria,30
respectively, and TLR3 has the highest protein expression,
among all TLR, in astrocytes.29 31 We also focused our investiga-
tion on these TLR because TLR2 signalling is restricted to
the classic MyD88-dependent pathway, TLR3 to the MyD88-
independent pathway and TLR4 is capable of signalling through
both ways.30 To perform western blot analysis, EGC were
homogenised in ice-cold hypotonic lysis buffer. The protein
concentration was determined by a protein assay kit (Bio-Rad).
For immunoblotting analysis, equivalent amounts of each sample
were denatured, separated on a sodium dodecyl sulfate-
polyacrylamide gel and transferred to a nitrocellulose membrane
(Amersham, Milan, Italy). The membranes were blocked for 2 h
at room temperature in 10% milk buffer and were incubated
overnight at 4°C with rabbit anti-TLR2 (1:500 vol/vol dilution;
Santa Cruz Biotechnology, Santa Cruz, California, USA), mouse
anti-CD283 (TLR3) (1:500; BD Biosciences, Franklin Lakes,
New Jersey, USA), rabbit anti-TLR4 (1:500; AbCam), mouse
anti-major histocompatibility complex (MHC) class II (1:500;
AbCam), or mouse anti-S100B (1:1000; AbCam) antibodies. For
experiments with TLR agonists, we used mouse anti-NF-κBp50
(1:250; Santa Cruz Biotechnology). To obtain nuclear extracts,
cells were homogenised in lysis buffer (10 mM HEPES pH 7.8,
10 mM KCl, 2 mM MgCl2, 1 mM dithiothreitol, 0.1 mM EDTA
and 0.1 mM phenylmethylsulfonyl fluoride). To the homogenate
was added 125 μl of 10% nonidet P-40 solution and the mixture
was then centrifuged at 14 000g. The pellet containing nuclei
was washed once with 0.4 ml of the same buffer plus 25 μl of
10% nonidet P-40, centrifuged, and resuspended in 100 μl of
nuclear extraction buffer (50 mM HEPES pH 7.8, 50 mM KCl,
0.3 M NaCl, 0.1 mM EDTA, 1 mM dithiothreitol, 0.1 mM phe-
nylmethylsulfonyl fluoride and 10% glycerol). After incubation
at 4°C for 20 min, the mixtures were centrifuged for 5 min at
14 000g. Subsequently, membranes were incubated for 2 h at
room temperature with the specific secondary antibody conju-
gated to horseradish peroxidase (AbCam). Western blots were
analysed by scanning densitometry (GS-700 imaging densitom-
eter; Bio-Rad) and the results were expressed as OD (arbitrary
units; mm2).
Immunocytochemistry
EGC were fixed at room temperature with freshly prepared par-
aformaldehyde 4%. After being washed in 0.1 M PBS, cells
were processed, as to block non-specific binding sites, with
0.1 M PBS with Triton-X and 10% goat serum (blocking buffer)
for 2 h at room temperature. Subsequently, for double-
immunofluorescence staining, EGC were exposed overnight at
4°C to primary antibodies: mouse anti-S100B (1:1000) or rabbit
anti-glial fibrillary acidic protein (GFAP) (1:1000; AbCam)—
two specific markers of EGC2 14 32—were used in combination
with rabbit anti-TLR2 (1:1000; Santa Cruz Biotechnology),
mouse anti-CD283 (TLR3) (1:1000; BD Biosciences), rabbit
anti-TLR4 (1:1000; AbCam), respectively, or with mouse
anti-MHC-II (1:1000; AbCam) or rabbit anti-cFos (1:1000;
AbCam) to assess cell activation. Nuclei were stained with
Hoechst. Negative controls were carried out by omitting the
primary antibodies. To test any non-specific antigen-binding
sites, additional experiments were performed using specific
isotype antibody controls (Imgenex Corp), at the same concen-
tration as the primary antibodies. After incubation, cells were
rinsed in 0.1 M PBS and incubated at room temperature for 1 h
with the specific secondary antibody diluted in blocking buffer
(Alexa Fluor 546 goat anti-mouse or Alexa fluor 488 goat anti-
rabbit; Invitrogen). Fluorescence was visualised on a Nikon
Eclipse E600 microscope (excitation filters Nikon 510–560 and
Nikon 470–490). Images were captured using a Nikon Coolpix
digital camera connected to the microscope, cropped using
Adobe Photoshop (Adobe Systems, San Jose, California, USA)
making minimal alterations (minor adjustments to brightness
and contrast) and finally transferred to Microsoft Powerpoint
for the creation of the figure sets. Fluorescence quantisation was
performed using ImageJ software V.1.42q33 34 (National
Institutes of Health).
Statistical analysis
Statistical analysis was performed with analysis of variance and
multiple comparisons with Bonferroni’s test. Data presented are
mean±SD of n experiments. The level of statistical significance
was set at p<0.05.
RESULTS
Purity of isolated EGC
Data on purity of EGC cultures are reported as supplementary
material (available online only) and have been reported
previously.17
EGC activation after exposure to bacteria
Figure 1 shows that, after 24 h exposure to EIEC, EGC
expressed MHC-II molecules (f ), which were not expressed in
basal conditions (b). In parallel, 24 h exposure to EIEC induced
the expression of the nuclear protein cFos (n)—considered to be
a cell activation marker,35 which was not expressed in basal con-
ditions ( j). MHC-II and cFos positivity was specifically localised
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and restricted to GFAP and S100B-positive EGC. We were not
able to detect MHC-II or cFos expression after 6 h exposure to
EIEC (data not shown). Western blot data, normalised on the
specific glial marker, GFAP, confirmed that MHC-II expression
was induced by EIEC (+160%±12 increase vs basal; p<0.05)
(figure 1C).
Cell mortality and pH values after exposure to bacteria
Data on cell mortality and pH values are reported as supple-
mentary data (available online only).
Baseline TLR mRNA expression in EGC
mRNA analysis by real-time PCR revealed that EGC physiolo-
gically express TLR. Figure 2 shows the baseline expression of
TLR. Based on the literature,29 TLR expression was categorised
into different ranges of expression, from high to rare. Whereas
TLR3 and TLR5 were expressed at an intermediate level
(5<ΔCT>15), other TLR were expressed at a very low level
compared to the housekeeping β-actin gene, with TLR7 and
TLR9 being the less expressed.
Modulation of TLR mRNA expression induced by
6 h exposure to pathogen and probiotic bacteria
Compared to basal conditions and after 6 h challenge with bac-
teria, TLR1 mRNA expression was significantly upregulated by
both EIEC and LP F19 (+9.4±1.0 and +10.3±1.0-fold increase
vs basal; p<0.01), as were TLR3 (+24.1±3.1 and +6.3
±0.5-fold increase vs basal; p<0.01) and TLR4 (+22.3±3.3 and
+26.0±2.2-fold increase vs basal; p<0.01). Conversely, TLR5
expression was significantly upregulated only by LP F19 (+2.0
±0.5-fold increase vs basal; p<0.01) (figure 3A).
The analysis of differences between viable pathogenic and pro-
biotic bacteria showed that after 6 h EIEC induced a significantly
higher TLR3 expression compared to LP F19 (+3.8±2.1-fold
increase vs LP F19; p<0.01). Conversely, compared to LP
F19, EIEC induced a significantly lower expression of
TLR5 (−9.9±2.0-fold decrease vs LP F19; p<0.01) and TLR7
(−16.3±3.1-fold decrease vs LP F19; p<0.01) (figure 3A).
Modulation of TLR mRNA expression induced by
24 h-exposure to pathogen and probiotic bacteria
Analysis of TLR mRNA levels in EGC stimulated with viable
pathogenic or probiotic bacteria revealed that, compared to
Figure 2 Baseline Toll-like receptors (TLR) mRNA expression on
enteric glial cells (EGC) by quantitative real-time PCR. mRNA analysis
revealed that EGC physiologically express all the TLR analysed. Baseline
mRNA levels for TLR were estimated by determining the difference
between the CT of the TLR gene of interest and the CT of the
endogenous control gene, β-actin. ΔCT values for each TLR were
categorised into different expression ranges, as described in the
Materials and methods section. In this graph, the highest is the ΔCT
value, the lowest is the expression. Each bar indicates the mean±SD of
n=8 independent determinations.
Figure 1 Enteric glial cell (EGC) activation following bacterial stimulation. (A) Immunocytochemistry showing major histocompatibility complex
(MHC) class II expression in EGC after 24 h exposure to the pathogen enteroinvasive Escherichia coli (EIEC). (B) Immunocytochemistry showing cFOS
expression in EGC after 24 h exposure to the pathogen EIEC. Immunofluorescence staining revealed both MHC-II (f; red) and cFOS (n; green)
expression in EGC (a, e: glial fibrillary acidic protein, green and i, m: S100B, red) after exposure to EIEC compared to unstimulated EGC (b and j,
respectively). Nuclei were stained with Hoechst (c, g, k, o). Panels d, h, l and p: merged. Note that in panel p cFOS co-localise with Hoechst.
Pictures are representative of n=5 independent immunofluorescence assays. Scale bars: 10 mm (a–d, m–p); 100 mm (e–l). (C) Western blot analysis
showing the protein expression of MHC-II in EIEC-stimulated compared to unstimulated EGC. The expression of MHC-II in cell homogenates is
shown in the upper panel, whereas the densitometric analysis of corresponding bands is represented in the graph and expressed as mm2 (arbitrary
units). Each bar shows the mean±SD of n=3 independent experiments. *p<0.05 versus basal.
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basal conditions, TLR2 expression was significantly upregulated
by both EIEC and LP F19 (+4.1±0.1 and +2.7±0.1-fold
increase vs basal; p<0.01), TLR3 expression was significantly
upregulated only by EIEC (+10.0±1.0-fold increase vs basal;
p<0.01), as were TLR7 (+8.0±0.2-fold increase vs basal;
p<0.01) and TLR9 (+8.8±1.7-fold increase vs basal; p<0.01).
TLR5 mRNA expression was significantly upregulated only by
LP F19 (+29.3±8.1-fold increase vs basal; p<0.01) (figure 3B).
The analysis of differences between pathogenic and probiotic
bacteria showed that, compared to LP F19, EIEC induced a sig-
nificantly higher expression of TLR2 (+1.5±0.1-fold increase
vs LP F19; p<0.01), TLR3 (+6.25±0.9-fold increase vs LP
F19; p<0.01), TLR7 (+4.7±0.5-fold increase vs LP F19;
p<0.01) and TLR9 (+8.0±1.2-fold increase vs LP F19;
p<0.01). Conversely, EIEC induced a lower TLR5 expression
than LP F19 (−10.1±2.4-fold decrease vs LP F19; p<0.01)
(figure 3B).
Different TLR mRNA expression induced by heat-inactivated
pathogens and probiotics
In order to gain more mechanistic insights, we also analysed TLR
mRNA expression after the incubation of EGC with heat-inacti-
vated pathogens and probiotics. Both the heat-inactivated LP F19
and EIEC induced a different TLR mRNA expression than the
viable bacteria.
After 6 h with the heat-inactivated EIEC, TLR2, TLR7 and
TLR9 expression was virtually undetectable (less than 0.1-fold
increase compared to basal) and only TLR5 expression was signifi-
cantly downregulated by heat-inactivated EIEC (−10.3±0.9-fold
decrease vs basal; p<0.01) (figure 4A). After 24 h, TLR2 expres-
sion remained lower than basal (−3.8±0.3-fold decrease vs basal;
p<0.01), while TLR7 and TLR9 expression did not significantly
differ from basal conditions. Conversely, heat-inactivated EIEC
significantly upregulated TLR3 (+18.3±1.5-fold increase vs basal;
p<0.01) and TLR4 expression (+6.0±0.6-fold increase vs basal;
p<0.01) (figure 4B). The analysis of differences between viable
and heat-inactivated EIEC showed that, after 6 h, TLR expression
induced by viable EIEC was significantly different from
heat-inactivated EIEC, with only TLR5 expression being the same
(figure 4A). After 24 h, the differences in TLR mRNA expression
induced by viable and heat-inactivated EIEC were less marked,
with TLR4 expression resulting in a higher response to
heat-inactivated EIEC than viable EIEC (figure 4B).
After 6 h with heat-inactivated probiotic bacteria TLR2,
TLR3, TLR7 and TLR9 expression was virtually undetectable
and TLR1, TLR4 and TLR5 expression did not significantly
differ from basal (figure 4C). After 24 h, TLR2 expression
remained lower than basal (−3.3±0.1-fold decrease vs basal;
p<0.01), while TLR4 expression was significantly increased
(+3.0±0.2-fold increase vs basal; p<0.01) (figure 4D). The
analysis of differences between viable and heath-inactivated LP
F19 showed that, as for EIEC, after 6 h there was a marked dif-
ference between viable and heath-inactivated bacteria that
trended to be less evident after 24 h (figure 4C,D).
Different TLR mRNA expression induced by bacterial-derived
soluble factors
After 6 h challenge with EIEC-derived soluble factors, TLR7
(+3.5±0.7-fold increase vs basal; p<0.01) and TLR9
(+12.1±2.9-fold increase vs basal; p<0.01) mRNA expression
was significantly upregulated compared to the basal condition
(figure 4A). After 24 h, EIEC-derived soluble factors induced the
upregulation of TLR7 (+5.8±1.6-fold increase vs basal; p<0.01)
and TLR9 (+6.9±1.1-fold increase vs basal; p<0.01) mRNA
(figure 4B).
With LP F19-derived soluble factors, after 6 h, TLR2 mRNA
was undetectable, TLR7 (+4.6±0.8-fold increase vs basal;
p<0.01) and TLR9 (+5.4±1.3-fold increase vs basal; p<0.01)
mRNA was significantly upregulated compared to the basal con-
dition (figure 4C). After 24 h, we observed a significant upregu-
lation of TLR7 (+5.7±1.6-fold increase vs basal; p<0.01) and
TLR9 (+12.2±2.9-fold increase vs basal; p<0.01) mRNA,
compared to the basal condition (figure 4D).
TLR protein expression in EGC induced by viable bacteria
Immunofluorescence shows that TLR2 protein was not, or only
barely, expressed in basal conditions but it was induced by both LP
F19 and EIEC after 24 h (+22.8±5.6 and +11.8±3.2-fold
increase vs basal, respectively; p<0.05) (figure 5A,B). We also per-
formed western blot analysis, normalising data on the enteroglial
marker GFAP, and we observed that TLR2 expression was
very low in basal conditions, data consistent with
Figure 3 Modulation of Toll-like receptor (TLR) expression induced by viable enteroinvasive Escherichia coli (EIEC) and Lactobacillus paracasei ssp.
paracasei F19 (LP F19). (A) Differences in TLR expression between viable EIEC (black bars) and viable LP F19 (grey bars) after 6 h of exposure. (B)
Differences in TLR expression between viable EIEC (black bars) and viable LP F19 (grey bars) after 24 h of exposure. Normalised fold expression of
each TLR were estimated by determining the ΔΔCT (ΔCT TREATMENT− ΔCT CONTROL). Data are expressed in a logarithmic scale as a fold increase
compared to controls (cells with medium alone). Each bar shows the mean±SD of n=5 independent determinations. *p<0.01 (vs basal); °p<0.01
(EIEC vs LP F19). Scale bars: 100 mm.
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immunocytochemistry and mRNA expression analysis. Both
pathogens and probiotics induced a significant upregulation of the
TLR2 protein (+96%±6.5 and +80±3.3 increase vs basal,
respectively; p<0.05) that was not revealed at the mRNA level
(figure 5C).
Despite the relatively robust expression at the mRNA level,
EGC did not express high levels of TLR3 protein at baseline,
after 24 h. Both pathogens and probiotics induced a significant
upregulation of TLR3 protein expression, as revealed by fluores-
cence (+5.5±0.8 and +6.4±1.0-fold increase vs basal; p<0.05)
and western blot (+78.1±6.6 and +120.0%±10.3 increase vs
basal; p<0.01) (figure 6).
Consistent with our findings on mRNA expression, after 24 h,
TLR4 levels were relatively high in basal conditions and both LP
F19 and EIEC were unable to induce significant differences in
protein expression, as revealed by fluorescence quantisation
(−0.65±0.1 and −0.61±0.2-fold decrease vs basal; p=NS) and
western blot analysis (−19%±5.2 and −6%±3.5-fold increase vs
basal; p=NS) (figure 7).
TLR2, TLR3 and TLR4 positivity was specifically localised
and restricted to EGC (GFAP and S100B-positive cells) (figures
5A, 6A and 7A). Although it is reported that TLR expression
has usually been shown to be located to the plasma membrane
and Golgi-associated vesicles, differences exist depending on cell
types and their differentiation state. Here we show that, in
EGC, TLR2 is detected mainly in the cytoplasm and in the
plasma membrane while for TLR3 and TLR4 the majority label
appears to be cytosolic and nuclear (Figures 5A, 6A and 7A).
After 6 h, TLR protein expression on EGC was very low and
not quantifiable (data not shown).
TLR-dependent NF-κB activation in EGC
Compared to basal conditions, western blot analysis of EGC
nuclear protein extract revealed that EIEC, but not LP F19,
induced nuclear translocation of NF-κBp50 protein (+1.99±0.38
and +0.56±0.19-fold increase vs basal; p<0.05) (figure 8A). Also
TLR2, TLR3 and TLR4 agonists induced a significant upregula-
tion of nuclear NF-kBp50 expression (+1.65±0.33, +2.03
±0.56, +1.79±0.39-fold increase vs basal; p<0.05) (figure 8A).
When EGC were treated with the specific MyD88-blocking
peptide, TLR2 and TLR4 agonists failed to induce NF-kBp50
nuclear translocation significantly (figure 8B). Only the TLR3
Figure 4 Effect of viable bacteria, heat-inactivated bacteria and bacterial-derived soluble factors on Toll-like receptor (TLR) expression in enteric
glial cells. (A) Differences in TLR expression between viable enteroinvasive Escherichia coli (EIEC) (black bars), heat-inactivated (white bars with
horizontal lines) and EIEC-derived soluble factors (white bars with diagonal lines) after 6 h of exposure and (B) after 24 h of exposure. (C)
Differences in TLR expression between viable Lactobacillus paracasei ssp. paracasei F19 (LP F19) (grey bars), heat-inactivated LP F19 (white bars
with dots) and LP F19-derived soluble factors (white bars with vertical lines) after 6 h of exposure and (D) after 24 h of exposure. Data are
expressed in a logarithmic scale as fold increase compared to basal conditions (cells with medium alone). Each bar shows the mean±SD of n=5
independent determinations. *p<0.01 (vs basal); °p<0.01 (vs heat-inactivated bacteria).
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agonist significantly increased NF-kBp50 nuclear protein expres-
sion (+1.75±0.33-fold increase vs basal; p<0.05 (figure 8B).
Figure 9 shows TLR2, TLR3 and TLR4 expression induced by
their respective agonists.
Bacterial-induced S100B protein expression
and NO production
After 24 h-exposure to the viable bacteria, we found that S100B
protein expression was significantly higher in response to EIEC
than to LP F19 compared to basal conditions (+2.9±0.2-fold
increase and +1.1±0.3-fold increase vs basal; p<0.01)
(figure 10A). Similarly, EIEC induced a significantly higher NO
release than LP F19 compared to basal conditions (13.9±3.7
and 2.3±1.1 nmol/106 cells vs 2.2±1.0 nmol/106 of control
cells; p<0.01) (figure 10B). S100B protein expression and NO
release induced by both heat-inactivated EIEC and LP F19 and
by bacterial-derived soluble factors were not significantly differ-
ent compared to basal conditions (data not shown).
Figure 5 Toll-like receptor 2 (TLR2) protein expression in enteric glial cells (EGC). (A) Immunofluorescence staining showing that in basal
conditions TLR2 protein was not expressed (b) while both Lactobacillus paracasei ssp. paracasei F19 (LP F19) (f ) and enteroinvasive Escherichia coli
(EIEC) ( j) induced TLR2 protein expression. The nuclei were stained with Hoechst (c, g, k). Panel d, h, l: merged. The pictures are representative of
n=3 independent immunofluorescence assays. Scale bars: 100 mm. (B) TLR2 corrected total cell fluorescence normalised on the number of cells of
the field. (C) Western blot analysis showing the protein expression of TLR2 in stimulated compared to unstimulated EGC. The expression of TLR2 in
cell homogenates is shown in the upper panel, whereas the densitometric analysis of corresponding bands is represented in the graph and is
expressed as mm2 (arbitrary units). TLR2 expression has been normalised on the expression of the glial marker glial fibrillary acidic protein. The
upper panel is representative of n=4 experiments. Each bar shows the mean±SD of n=4 independent experiments. *p<0.05 versus basal.
Figure 6 Toll-like receptor 3 (TLR3) protein expression in enteric glial cells (EGC). (A) Immunofluorescence staining showing that TLR3 protein was
weakly expressed under basal conditions (b) while both Lactobacillus paracasei ssp. paracasei F19 (LP F19) (f ) and enteroinvasive Escherichia coli
(EIEC) ( j) induced TLR2 protein expression. The nuclei were stained with Hoechst (c, g, k). Panel d, h, l: merged. The pictures are representative of
n=3 independent immunofluorescence assays. Scale bars: 100 mm. (B) TLR3 corrected total cell fluorescence normalised on the number of cells of
the field. (C) Western blot analysis showing protein expression of TLR3 in stimulated compared to unstimulated EGC. The expression of TLR3 in cell
homogenates is shown in the upper panel, whereas the densitometric analysis of the corresponding bands is represented in the graph and is
expressed as mm2 (arbitrary units). TLR3 expression has been normalised on the expression of the glial marker glial fibrillary acidic protein (GFAP).
The upper panel is representative of n=4 experiments. Each bar shows the mean±SD of n=4 independent experiments. *p<0.05 versus basal.
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Effect of anti-S100B, anti-RAGE and anti-MyD88
on S100B protein expression and NO production
EIEC-induced S100B upregulation was associated with NO pro-
duction, because preincubation with the specific S100B-blocking
antibody, added 2 h before exposure to EIEC, impaired NO
release from EGC (+1.0±0.3-fold increase vs basal; p=NS)
(figure 10C). As expected, the same result was obtained by treat-
ing EGC for 2 h with the specific RAGE-blocking antibody
(+1.1±0.3-fold increase vs basal; p=NS) (figure 10C). To
evaluate whether the TLR pathway was also involved in NO
release, EGC were preincubated with the specific
MyD88-blocking peptide and, similarly to anti-S100B and
anti-RAGE, this condition led to impaired NO production (1.1
±0.4-fold increase vs basal; p=NS) (figure 10C). Neither
anti-S100B, anti-RAGE nor anti-MyD88 affected EIEC-induced
S100B protein expression (data not shown). This suggests the
presence of a common pathway linking S100B, RAGE and
MyD88, a downstream signal characteristic of all TLR, with the
exception of TLR3.
DISCUSSION
Various studies in animal models have greatly contributed to elu-
cidate EGC functions, indicating that these cells are involved in
the regulation of intestinal pathophysiological events.2–7 14 15 17
However, only a few studies have translated the data obtained
from animal models to humans. Here, we describe a novel and
potentially important function of human EGC, highlighting
their ability to be activated and to interact with bacteria, thus
playing an active role in host–bacteria crosstalk. We also show
how enteroglial-derived S100B protein is able to integrate the
TLR signalling involved in NO release.
We recently demonstrated that human EGC are activated by
exogenous stimuli.14 15 17 In the present study, we provide evi-
dence that EGC are also activated by invading microorganisms,
such as enteroinvasive bacteria, and that this activation induces
the expression of MHC-II and cFos proteins. These data
confirm previous observations suggesting that EGC may interact
with bacteria,6 7 and point out the role of EGC in the regulation
of the host–bacteria interplay also in humans.
Innate immunity in the brain is controlled primarily by TLR
expressed on glial cells, especially astrocytes and microglia. In
healthy conditions, astrocytes barely express TLR, but their
expression is rapidly upregulated following bacterial invasion.36
We observed that EGC share with astrocytes the potential role
of resident immune sentinels, as they express TLR at baseline,
although only TLR3 and TLR5 mRNA were expressed at the
intermediate level, while basal expression of other TLR was
very low. These findings indicate that EGC, together with the
ability to be activated by exogenous insults and bacteria, also
possess the molecular mechanisms potentially able to trigger
innate immunity in the gut.
In order to gain more mechanistic insights into TLR response
and to evaluate whether TLR expression on EGC is modulated
by bacteria, we set up a co-culture model of EGC bacteria. Our
data showed that TLR mRNA expression is differentially modu-
lated by pathogens and probiotics. Together with gene expres-
sion, we also demonstrated protein expression of TLR2, TLR3
and TLR4. TLR2 and TLR4 basal protein expression was consist-
ent with mRNA levels, while despite a relatively robust basal
mRNA expression, TLR3 protein expression was very low. The
reasons for the lack of correlation between mRNA and protein
expression are unclear but, as proposed by other studies,37 38 this
may indicate the presence of post-translational mechanisms for
the regulation of protein abundance. We also showed that
protein expression of TLR2 and TLR3 can be differentially
modulated by pathogens and probiotics. Indeed, LP F19 induced
higher TLR2 expression than EIEC, while TLR3 expression is
higher in response to EIEC than to LP F19. This is consistent
with data from the literature, because TLR2 detects mainly
Gram-positive bacteria,30 while TLR3, in astrocytes, is upregu-
lated in response to bacterial products.39 This differently induced
TLR expression may indicate the heterogeneity of cellular
response to pathogens or probiotics, suggesting that in human
EGC the mechanisms of bacterial recognition are tailored to the
Figure 7 Toll-like receptor 4 (TLR4) protein expression in enteric glial cells (EGC). (A) Immunofluorescence staining showing that in basal conditions
TLR4 protein was expressed (b) and neither Lactobacillus paracasei ssp. paracasei F19 (LP F19) (f ) nor enteroinvasive Escherichia coli (EIEC) ( j) were
able to induce a significant increase in TLR4 protein expression. The nuclei were stained with Hoechst (c, g, k). Panel d, h, l: merged. Pictures are
representative of n=3 independent immunofluorescence assays. Scale bars: 100 mm. (B) TLR4 corrected total cell fluorescence normalised on the
number of cells of the field. (C) Western blot analysis showing protein expression of TLR4 in stimulated compared to unstimulated EGC. The expression
of TLR4 in cell homogenates is shown in the upper panel, whereas the densitometric analysis of corresponding bands is represented in the graph and is
expressed as mm2 (arbitrary units). TLR2 expression has been normalised on the expression of the glial marker glial fibrillary acidic protein (GFAP). The
upper panel is representative of n=4 experiments. Each bar shows the mean±SD of n=4 independent experiments.
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type of bacteria involved. TLR expression may also be influenced
by the diverse localisation of the bacteria, as EIEC, on infection,
has intracellular localisation,40 while probiotic strain localisation
is extracellular.41 In addition, heat-inactivated bacteria were also
able to modulate TLR mRNA expression differently, although to
a lesser extent than viable bacteria. The data on heat-inactivated
bacteria indicate that EIEC and LP F19 effects on EGC are not
only mediated by soluble factors. Soluble factors have their
importance in modulating TLR mRNA expression because data
obtained after treatment with pathogen or probiotic-derived
soluble factors show different TLR expression, compared to
basal conditions and to live bacteria. Based on these results, it
would be of extreme interest to determine which bacterial struc-
tural components or which released soluble factors are able to
induce a TLR-mediated response in human EGC.
In order to prove the effective functionality of TLR on EGC,
we analysed the protein expression of NF-κB, which is consid-
ered the main effector of TLR activation.30 We found that TLR2,
TLR3 and TLR4 agonists were able to induce NF-κBp50 nuclear
translocation in EGC. Consistent with the literature, we provided
evidence that by inhibiting MyD88, an important mediator of
almost all the TLR downstream signalling, the TLR2 agonist
failed to induce NF-κBp50 expression and the TLR4 agonist
induced only a weak, not significant, NF-κBp50 expression. As
TLR3 signalling is MyD88-independent, the TLR3 agonist (Poly
I:C) was able to induce NF-κBp50 expression in EGC
significantly.
Sensing the presence of pathogens to mount the effective
response is the main role of TLR. TLR activation, via iNOS
induction, leads to increased NO production.11 12 In our previ-
ous works, we observed increased NO release when EGC were
challenged with bacterial lipopolysaccharide.13 14 NO produc-
tion was correlated with the upregulation of enteroglial-derived
S100B protein. The data presented here show that S100B protein
expression is also upregulated when EGC are challenged with
pathogenic EIEC, but not with probiotic LP F19. This upregula-
tion was related to the increased NO production from EGC.
Indeed, as expected, blocking S100B with the specific antibody
resulted in impaired EIEC-induced NO production.
Given the fact that both S100B and TLR-mediated pathways
lead to NO production, we have addressed the issue of whether
and how the two systems interact. A major finding of this study
suggests that S100B is able to integrate TLR signalling in EGC.
As reported in the literature, S100B exerts many effects by inter-
acting with the multiligand receptor RAGE.42 43 When RAGE
was blocked with the specific antibody, NO production was
impaired. However, and most interestingly, we provide evidence
that the inhibition of MyD88, an important mediator of almost
all the TLR downstream signalling, also resulted in impaired NO
production, without affecting S100B expression. As RAGE is also
associated with the TLR pathway,16 these findings suggest that
RAGE may act as a molecular link between the S100B and TLR
pathways, which, once activated, leads to NO production from
EGC. We can speculate that when a specific insult (ie, lipopoly-
saccharide or a pathogenic bacteria) upregulates S100B expres-
sion, this protein interacts with RAGE, which is expressed on the
surface of EGC. As proposed by other studies, the S100B/RAGE
complex may be internalised within the cell and,43 44 here, inter-
act, directly or not, with MyD88, thus inducing iNOS expression
and NO release. This suggestive hypothesis needs to be con-
firmed by further investigations. Nonetheless, these preliminary
data confirm the role of the enteroglial-derived S100B protein as
an active player in host–bacteria interaction.
In summary, in this study we demonstrated, for the first time,
that human-derived EGC express TLR and directly interact with
bacteria. The potential role of EGC in triggering innate immune
responses is emphasised by the demonstration that these cells
not only express TLR, but are able to discriminate between
pathogens and probiotics by modulating TLR expression. Our
data show that EGC adequately respond to bacterial insults (ie,
releasing NO) and, possibly, they play a role in modulating
nitrosative stress. NO release from EGC involves both S100B
and TLR-mediated pathways, and the interference with these
targets might be an efficient therapeutic strategy to modulate
abnormal NO production within the gut. In addition, we
showed that TLR expression in EGC is specifically regulated by
the type of bacteria interacting with them, and that NO produc-
tion consequent to such contact depends on both TLR and
S100B\RAGE involvement, suggesting the presence of a novel
common pathway leading to NO production. This study lays
the basis to further considering EGC as active participants in
host–bacteria crosstalk.
Figure 8 Nuclear factor κB (NF-κB)p50 expression in nuclear lysates
from enteric glial cells (EGC). (A) Western blot analysis showing that
NF-κBp50 protein expression is significantly upregulated in response to
Toll-like receptor (TLR) agonists and enteroinvasive Escherichia coli
(EIEC) but not to Lactobacillus paracasei ssp. paracasei F19 (LP F19).
(B) Western blot analysis showing that: TLR2 agonist zymosan failed to
induce NF-κBp50 expression when EGC were preincubated with
MyD88; TLR3 agonist poly (I:C) significantly upregulated NF-κB
expression compared to unstimulated EGC; TLR4 agonist
lipopolysaccharide (LPS) induced a non-significant upregulation of
NF-κBp50 expression. Upper panels show NF-κB in nuclear
homogenates and are representative of n=3 experiments. The graphs
show the densitometric analysis (arbitrary units) and are representative
of n=3 experiments. *p<0.05 versus basal.
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Based on our present results and previous studies,4–7 it could
be of extreme interest to translate these observational data into
animal models, in order to determine whether the modulation
of TLR receptors and the regulation of NO production
observed in vitro also exist in vivo.
In conclusion, although further studies are required to define
better the role of EGC in the host–bacteria interaction and the
exact mechanisms involved in NO production, our findings high-
light a novel role for EGC, demonstrating that they differentially
sense the presence of harmful or healthy bacteria in the gut.
Figure 9 Toll-like receptor (TLR) expression in enteric glial cells (EGC) induced by TLR agonists. Immunofluorescence staining showing: S100B (a)
and TLR2 (b) expression induced by TLR2 agonist zymosan; glial fibrillary acidic protein (GFAP) (e) and TLR3 (f ) expression induced by TLR3 agonist
poly (I:C). S100B (i) and TLR2 ( j) expression induced by TLR4 agonist lipopolysaccharide. Nuclei were stained with Hoechst (c, g, k). Panel d, h, l:
merged. Pictures are representative of n=3 independent immunofluorescence assays. Scale bars: 40 mm.
Figure 10 S100B expression and nitric oxide (NO) production induced by bacteria. (A) Western blot analysis showing that S100B protein
expression is significantly upregulated in response to enteroinvasive Escherichia coli (EIEC) but not in response to Lactobacillus paracasei ssp.
paracasei F19 (LP F19). The upper panel shows S100B in cell homogenates, and is representative of n=3 experiments. The graph shows
densitometric analysis (arbitrary units). *p<0.01 versus basal. (B) The analysis of nitrite levels revealed that EIEC, but not LP F19, significantly
increased NO production in EGC. NO production was determined by measuring the accumulation of nitrite in the culture medium of 24 h EGC
bacteria cultures. Each bar shows the mean±SD of n=10 experiments. *p<0.01 versus basal. (D) EIEC stimulation for 24 h failed to increase NO
production when EGC were preincubated with anti-S100B antibody, anti-receptor for advanced glycation endproducts antibody or anti-MyD88
blocking peptide, respectively. Each bar shows the mean±SD of n=10 independent experiments.
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